Atherogenic Index Of Plasma As An Early Marker Of Diabetic Kidney Disease In Type 2 Diabetes Mellitus at RLJ Hospital, Kolar
Abstract
Background: Diabetic kidney disease (DKD) remains a leading cause of end-stage kidney disease among individuals with type 2 diabetes mellitus (T2DM). Early detection hinges on accessible biomarkers that anticipate microalbuminuria and early estimated glomerular filtration rate (eGFR) decline. The atherogenic index of plasma (AIP), defined as log₁₀(triglycerides/HDL-cholesterol) in molar units, integrates atherogenic dyslipidemia and has been linked to microvascular injury in diabetes. Methods : We conducted a hospital-based, cross-sectional study in the Department of General Medicine, RLJ Hospital, Kolar. Consecutive adults with T2DM (age 45–85 years) were enrolled over three months. Exclusions included type 1 diabetes, urinary protein–creatinine ratio >1000 mg/g, or eGFR <30 mL/min/1.73 m². After ≥8-hour fasting, venous samples were analyzed for fasting glucose, lipid profile, uric acid, creatinine, and HbA1c; urine was assessed for albumin and creatinine. AIP was computed from triglycerides and HDL-C. Outcomes included albuminuria categories (A1–A3) and eGFR (CKD-EPI 2021). Associations between AIP and DKD metrics were examined using correlation and multivariable models adjusting for age, sex, diabetes duration, blood pressure, body mass index, and HbA1c. Results : In this pragmatic inpatient cohort, higher AIP values tracked with worsening albuminuria categories and lower eGFR. AIP showed a positive, moderate correlation with HbA1c and triglycerides and an inverse correlation with HDL-C. In adjusted analyses, AIP remained independently associated with albuminuria status. Exploratory discrimination analyses suggested that AIP improved reclassification for DKD beyond HbA1c and blood pressure. Conclusion : AIP—an inexpensive, routinely available composite of triglycerides and HDL-C—demonstrated independent associations with early DKD markers in T2DM at RLJ Hospital. Incorporating AIP into routine metabolic panels may bolster early DKD risk stratification alongside HbA1c and blood pressure control, particularly in resource-constrained settings.